Get the Stockscreener App
1.79
2.87%
0.05
After Hours:
1.79
Nkarta Inc stock is traded at $1.79, with a volume of 959.15K.
It is up +2.87% in the last 24 hours and down -35.14% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$1.74
Open:
$1.74
24h Volume:
959.15K
Relative Volume:
0.82
Market Cap:
$128.21M
Revenue:
Net Income/Loss:
$-104.08M
P/E Ratio:
-1.2723
EPS:
-1.4069
Net Cash Flow:
$-89.91M
1W Performance:
-0.56%
1M Performance:
-35.14%
6M Performance:
-39.93%
1Y Performance:
-20.80%
1-Day Range:
$1.66
$1.81
1-Week Range:
$1.66
$1.85
52-Week Range:
$1.66
$3.72
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.79 | 128.21M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-26 | Initiated | TD Cowen | Buy |
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - The Manila Times
Nkarta (NKTX) Edges Higher to $2.58 as Traders Watch $2.45 Support and $2.71 ResistanceATR Trailing Stop - siam.in
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance UK
Stifel reiterates Buy rating on Nkarta stock, cites trial progress By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Nkarta stock, cites trial progress - Investing.com
Stifel reiterates Buy rating on Nkarta stock, cites trial progress By Investing.com - Investing.com UK
Nkarta to Participate in September Investor Conferences - Investing News Network
Two Nkarta investor talks will be webcast in September - Stock Titan
Nkarta Insiders Got A Good Deal Selling At US$2.10 - simplywall.st
Nkarta to Present Initial Autoimmune Clinical Data for - GlobeNewswire
Nkarta’s autoimmune cell therapy will get two talks and a poster - Stock Titan
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders - Seeking Alpha
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (yKkQAHM32g) - Mshale
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - Kalkine
Dare Bioscience Prices $6.0 Million Registered Direct Offering - minichart.com.sg
Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX) - The Globe and Mail
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Australia
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Canada
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Nigeria
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com India
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com UK
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - MarketBeat
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - kalkine.ca
Nkarta Inc. (NKTX) Edges Higher as Biotech Stock Holds Key Support ZoneEase of Movement - vinanet.vn
Nkarta Inc. (NKTX) Edges Higher as Biotech Stock Holds Key Support ZoneHigh Conviction Picks - dars.gov.et
Equities Analysts Set Expectations for Nkarta Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (yKkQAHM32g) - Mshale
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside - TradingView
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
H.C. Wainwright cuts Nkarta stock price target on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright cuts Nkarta stock price target on trial progress By Investing.com - Investing.com UK
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16 - Bitget
NKTX Q2 2026 Earnings: Wider Loss of $0.54 Per Share Misses Estimates as Clinical-Stage Costs EscalateFinancial Data - vinanet.vn
Nkarta, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS - MarketBeat
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate - scanx.trade
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029 - Quiver Quantitative
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports 5.24% Share GainROIC Trend Report - vinanet.vn
Nkarta, Inc. expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '26 |
Sale |
2.07 |
26,046 |
53,915 |
390,023 |
| Mahmood Nadir | President |
Jan 15 '26 |
Sale |
2.07 |
5,649 |
11,693 |
167,727 |
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):